|
|
Targeted therapy of desmoid-type fibromatosis: mechanism, current situation, and future prospects |
Zhen Wang, Jianhui Wu, Xiuyun Tian, Chunyi Hao() |
Key Laboratory of Carcinogenesis and Translational Research, Ministry of Education, Department of Hepato–Pancreato–Biliary Surgery, Peking University Cancer Hospital and Institute, Beijing 100142, China |
|
|
Abstract Desmoid-type fibromatosis (DF) is a rare monoclonal fibroblastic proliferation that is characterized by locally infiltrative but rarely metastatic lesions. Tyrosine kinase and γ-secretase inhibitors are primarily used in the targeted therapy of DF. The use of these drugs, however, is mainly based on the recommendations of retrospective studies with small sample sizes. Previous studies that focused on the mechanism, efficacy, and safety of targeted therapy for DF were reviewed to provide references for clinical applications and research. The efficacy and safety of targeted therapy were compared with those of other systemic therapy options. Targeted therapy does not provide considerable advantages in efficacy and safety over other medical treatments and is usually applied after the failure of antihormonal therapies, nonsteroidal anti-inflammatory drugs, and chemotherapy. Further studies are required to explore the mechanism, indications, and appropriate drug dosage of the targeted therapy of DF.
|
Keywords
targeted therapy
desmoid-type fibromatosis
tyrosine kinase inhibitor
γ-secretase inhibitor
|
Corresponding Author(s):
Chunyi Hao
|
Just Accepted Date: 28 December 2018
Online First Date: 22 February 2019
Issue Date: 02 August 2019
|
|
1 |
B Kasper, C Baumgarten, J Garcia, S Bonvalot, R Haas, F Haller, P Hohenberger, N Penel, C Messiou, WT van der Graaf, A Gronchi; Desmoid Working Group. An update on the management of sporadic desmoid-type fibromatosis: a European Consensus Initiative between Sarcoma PAtients EuroNet (SPAEN) and European Organization for Research and Treatment of Cancer (EORTC)/Soft Tissue and Bone Sarcoma Group (STBSG). Ann Oncol 2017; 28(10): 2399–2408
https://doi.org/10.1093/annonc/mdx323
pmid: 28961825
|
2 |
S Otero, EC Moskovic, DC Strauss, C Benson, AB Miah, K Thway, C Messiou. Desmoid-type fibromatosis. Clin Radiol 2015; 70(9): 1038–1045
https://doi.org/10.1016/j.crad.2015.04.015
pmid: 26162574
|
3 |
L Bertario, A Russo, P Sala, M Eboli, M Giarola, F D’amico, V Gismondi, L Varesco, MA Pierotti, P; Hereditary Colorectal Tumours Registry. Radice Genotype and phenotype factors as determinants of desmoid tumors in patients with familial adenomatous polyposis. Int J Cancer 2001; 95(2): 102–107
https://doi.org/10.1002/1097-0215(20010320)95:2<102::AID-IJC1018>3.0.CO;2-8
pmid: 11241320
|
4 |
KM Skubitz. Biology and treatment of aggressive fibromatosis or desmoid tumor. Mayo Clin Proc 2017; 92(6): 947–964
https://doi.org/10.1016/j.mayocp.2017.02.012
pmid: 28578783
|
5 |
AJ Lazar, D Tuvin, S Hajibashi, S Habeeb, S Bolshakov, E Mayordomo-Aranda, CL Warneke, D Lopez-Terrada, RE Pollock, D Lev. Specific mutations in the β-catenin gene (CTNNB1) correlate with local recurrence in sporadic desmoid tumors. Am J Pathol 2008; 173(5): 1518–1527
https://doi.org/10.2353/ajpath.2008.080475
pmid: 18832571
|
6 |
BA Alman, C Li, ME Pajerski, S Diaz-Cano, HJ Wolfe. Increased β-catenin protein and somatic APC mutations in sporadic aggressive fibromatoses (desmoid tumors). Am J Pathol 1997; 151(2): 329–334
pmid: 9250146
|
7 |
S Salas, F Chibon, T Noguchi, P Terrier, D Ranchere-Vince, P Lagarde, J Benard, S Forget, C Blanchard, J Dômont, S Bonvalot, L Guillou, A Leroux, A Mechine-Neuville, P Schöffski, M Laë, F Collin, O Verola, A Carbonnelle, L Vescovo, B Bui, V Brouste, H Sobol, A Aurias, JM Coindre. Molecular characterization by array comparative genomic hybridization and DNA sequencing of 194 desmoid tumors. Genes Chromosomes Cancer 2010; 49(6): 560–568
https://doi.org/10.1002/gcc.20766
pmid: 20232483
|
8 |
S Le Guellec, I Soubeyran, P Rochaix, T Filleron, A Neuville, I Hostein, JM Coindre. CTNNB1 mutation analysis is a useful tool for the diagnosis of desmoid tumors: a study of 260 desmoid tumors and 191 potential morphologic mimics. Mod Pathol 2012; 25(12): 1551–1558
https://doi.org/10.1038/modpathol.2012.115
pmid: 22766794
|
9 |
C Colombo, R Miceli, AJ Lazar, F Perrone, RE Pollock, A Le Cesne, HH Hartgrink, AM Cleton-Jansen, J Domont, JV Bovée, S Bonvalot, D Lev, A Gronchi. CTNNB1 45F mutation is a molecular prognosticator of increased postoperative primary desmoid tumor recurrence: an independent, multicenter validation study. Cancer 2013; 119(20): 3696–3702
https://doi.org/10.1002/cncr.28271
pmid: 23913621
|
10 |
DL van Broekhoven, C Verhoef, DJ Grünhagen, JM van Gorp, MA den Bakker, JW Hinrichs, CM de Voijs, T van Dalen. Prognostic value of CTNNB1 gene mutation in primary sporadic aggressive fibromatosis. Ann Surg Oncol 2015; 22(5): 1464–1470
https://doi.org/10.1245/s10434-014-4156-x
pmid: 25341748
|
11 |
M Lacroix-Triki, FC Geyer, MB Lambros, K Savage, IO Ellis, AH Lee, JS Reis-Filho. β-catenin/Wnt signalling pathway in fibromatosis, metaplastic carcinomas and phyllodes tumours of the breast. Mod Pathol 2010; 23(11): 1438–1448
https://doi.org/10.1038/modpathol.2010.141
pmid: 20693983
|
12 |
J Couture, A Mitri, R Lagace, R Smits, T Berk, HL Bouchard, R Fodde, B Alman, B Bapat. A germline mutation at the extreme 3′ end of the APC gene results in a severe desmoid phenotype and is associated with overexpression of β-catenin in the desmoid tumor. Clin Genet 2000; 57(3): 205–212
https://doi.org/10.1034/j.1399-0004.2000.570306.x
pmid: 10782927
|
13 |
JC Harvey, SH Quan, JG Fortner. Gardner’s syndrome complicated by mesenteric desmoid tumors. Surgery 1979; 85(4): 475–477
pmid: 432809
|
14 |
C Colombo, R Miceli, C Le Péchoux, E Palassini, C Honoré, S Stacchiotti, O Mir, PG Casali, J Dômont, M Fiore, A Le Cesne, A Gronchi, S Bonvalot. Sporadic extra abdominal wall desmoid-type fibromatosis: surgical resection can be safely limited to a minority of patients. Eur J Cancer 2015; 51(2): 186–192
https://doi.org/10.1016/j.ejca.2014.11.019
pmid: 25500145
|
15 |
B Kasper, C Baumgarten, S Bonvalot, R Haas, F Haller, P Hohenberger, G Moreau, WT van der Graaf, A; Desmoid Working Group. Gronchi Management of sporadic desmoid-type fibromatosis: a European consensus approach based on patients’ and professionals’ expertise — a sarcoma patients EuroNet and European Organisation for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group initiative. Eur J Cancer 2015; 51(2): 127–136
https://doi.org/10.1016/j.ejca.2014.11.005
pmid: 25434922
|
16 |
S Bonvalot, H Eldweny, V Haddad, F Rimareix, G Missenard, O Oberlin, D Vanel, P Terrier, JY Blay, A Le Cesne, C Le Péchoux. Extra-abdominal primary fibromatosis: aggressive management could be avoided in a subgroup of patients. Eur J Surg Oncol 2008; 34(4): 462–468
https://doi.org/10.1016/j.ejso.2007.06.006
pmid: 17709227
|
17 |
M Fiore, F Rimareix, L Mariani, J Domont, P Collini, C Le Péchoux, PG Casali, A Le Cesne, A Gronchi, S Bonvalot. Desmoid-type fibromatosis: a front-line conservative approach to select patients for surgical treatment. Ann Surg Oncol 2009; 16(9): 2587–2593
https://doi.org/10.1245/s10434-009-0586-2
pmid: 19568815
|
18 |
S Briand, O Barbier, D Biau, A Bertrand-Vasseur, F Larousserie, P Anract, F Gouin. Wait-and-see policy as a first-line management for extra-abdominal desmoid tumors. J Bone Joint Surg Am 2014; 96(8): 631–638
https://doi.org/10.2106/JBJS.M.00988
pmid: 24740659
|
19 |
B Kasper, V Gruenwald, P Reichardt, S Bauer, G Rauch, R Limprecht, M Sommer, A Dimitrakopoulou-Strauss, L Pilz, F Haller, P Hohenberger. Imatinib induces sustained progression arrest in RECIST progressive desmoid tumours: final results of a phase II study of the German Interdisciplinary Sarcoma Group (GISG). Eur J Cancer 2017; 76: 60–67
https://doi.org/10.1016/j.ejca.2017.02.001
pmid: 28282612
|
20 |
N Penel, A Le Cesne, BN Bui, D Perol, EG Brain, I Ray-Coquard, C Guillemet, C Chevreau, D Cupissol, S Chabaud, M Jimenez, F Duffaud, S Piperno-Neumann, L Mignot, JY Blay. Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French Sarcoma Group phase II trial with a long-term follow-up. Ann Oncol 2011; 22(2): 452–457
https://doi.org/10.1093/annonc/mdq341
pmid: 20622000
|
21 |
S Kummar, G O’Sullivan Coyne, KT Do, B Turkbey, PS Meltzer, E Polley, PL Choyke, R Meehan, R Vilimas, Y Horneffer, L Juwara, A Lih, A Choudhary, SA Mitchell, LJ Helman, JH Doroshow, AP Chen. Clinical activity of the g-secretase inhibitor PF-03084014 in adults with desmoid tumors (aggressive fibromatosis). J Clin Oncol 2017; 35(14): 1561–1569
https://doi.org/10.1200/JCO.2016.71.1994
pmid: 28350521
|
22 |
Z Szucs, C Messiou, HH Wong, H Hatcher, A Miah, S Zaidi, WT van der Graaf, I Judson, RL Jones, C Benson. Pazopanib, a promising option for the treatment of aggressive fibromatosis. Anticancer Drugs 2017; 28(4): 421–426
https://doi.org/10.1097/CAD.0000000000000474
pmid: 28099210
|
23 |
C Brogsitter, D Faulhaber, J Kotzerke. Intraarterial treatment of GEP NET: (68)Ga-DOTATOC SUV cannot predict (90)Y-DOTATOC uptake. Clin Cancer Res 2011; 17(7): 2065
https://doi.org/10.1158/1078-0432.CCR-10-1970
pmid: 21447724
|
24 |
KM Skubitz, JC Manivel, DR Clohisy, JW Frolich. Response of imatinib-resistant extra-abdominal aggressive fibromatosis to sunitinib: case report and review of the literature on response to tyrosine kinase inhibitors. Cancer Chemother Pharmacol 2009; 64(3): 635–640
https://doi.org/10.1007/s00280-009-1010-0
pmid: 19404642
|
25 |
E Buchdunger, CL Cioffi, N Law, D Stover, S Ohno-Jones, BJ Druker, NB Lydon. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000; 295(1): 139–145
pmid: 10991971
|
26 |
J Mace, J Sybil Biermann, V Sondak, C McGinn, C Hayes, D Thomas, L Baker. Response of extraabdominal desmoid tumors to therapy with imatinib mesylate. Cancer 2002; 95(11): 2373–2379
https://doi.org/10.1002/cncr.11029
pmid: 12436445
|
27 |
M Carroll, S Ohno-Jones, S Tamura, E Buchdunger, J Zimmermann, NB Lydon, DG Gilliland, BJ Druker. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood 1997; 90(12): 4947–4952
pmid: 9389713
|
28 |
MC Heinrich, GA McArthur, GD Demetri, H Joensuu, P Bono, R Herrmann, H Hirte, S Cresta, DB Koslin, CL Corless, S Dirnhofer, AT van Oosterom, Z Nikolova, S Dimitrijevic, JA Fletcher. Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor). J Clin Oncol 2006; 24(7): 1195–1203
https://doi.org/10.1200/JCO.2005.04.0717
pmid: 16505440
|
29 |
G Wcislo, K Szarlej-Wcislo, C Szczylik. Control of aggressive fibromatosis by treatment with imatinib mesylate. A case report and review of the literature. J Cancer Res Clin Oncol 2007; 133(8): 533–538
https://doi.org/10.1007/s00432-007-0198-9
pmid: 17453242
|
30 |
R Chugh, JK Wathen, SR Patel, RG Maki, PA Meyers, SM Schuetze, DA Priebat, DG Thomas, JA Jacobson, BL Samuels, RS Benjamin, LH; Sarcoma Alliance for Research through Collaboration (SARC). Baker Efficacy of imatinib in aggressive fibromatosis: results of a phase II multicenter Sarcoma Alliance for Research through Collaboration (SARC) trial. Clin Cancer Res 2010; 16(19): 4884–4891
https://doi.org/10.1158/1078-0432.CCR-10-1177
pmid: 20724445
|
31 |
J Verweij, PG Casali, J Zalcberg, A LeCesne, P Reichardt, JY Blay, R Issels, A van Oosterom, PC Hogendoorn, M Van Glabbeke, R Bertulli, I Judson. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004; 364(9440): 1127–1134
https://doi.org/10.1016/S0140-6736(04)17098-0
pmid: 15451219
|
32 |
JR Zalcberg, J Verweij, PG Casali, A Le Cesne, P Reichardt, JY Blay, M Schlemmer, M Van Glabbeke, M Brown, IR Judson; EORTC Soft Tissue and Bone Sarcoma Group, the Italian Sarcoma Group; Australasian Gastrointestinal Trials Group. Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. Eur J Cancer 2005; 41(12): 1751–1757
https://doi.org/10.1016/j.ejca.2005.04.034
pmid: 16098458
|
33 |
CD Blanke, C Rankin, GD Demetri, CW Ryan, M von Mehren, RS Benjamin, AK Raymond, VH Bramwell, LH Baker, RG Maki, M Tanaka, JR Hecht, MC Heinrich, CD Fletcher, JJ Crowley, EC Borden. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 2008; 26(4): 626–632
https://doi.org/10.1200/JCO.2007.13.4452
pmid: 18235122
|
34 |
E Weisberg, P Manley, J Mestan, S Cowan-Jacob, A Ray, JD Griffin. AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL. Br J Cancer 2006; 94(12): 1765–1769
https://doi.org/10.1038/sj.bjc.6603170
pmid: 16721371
|
35 |
JY Blay, M von Mehren. Nilotinib: a novel, selective tyrosine kinase inhibitor. Semin Oncol 2011; 38(Suppl 1): S3–S9
https://doi.org/10.1053/j.seminoncol.2011.01.016
pmid: 21419934
|
36 |
PW Manley, N Stiefl, SW Cowan-Jacob, S Kaufman, J Mestan, M Wartmann, M Wiesmann, R Woodman, N Gallagher. Structural resemblances and comparisons of the relative pharmacological properties of imatinib and nilotinib. Bioorg Med Chem 2010; 18(19): 6977–6986
https://doi.org/10.1016/j.bmc.2010.08.026
pmid: 20817538
|
37 |
PW Manley, P Drueckes, G Fendrich, P Furet, J Liebetanz, G Martiny-Baron, J Mestan, J Trappe, M Wartmann, D Fabbro. Extended kinase profile and properties of the protein kinase inhibitor nilotinib. Biochim Biophys Acta 2010; 1804(3): 445–453
https://doi.org/10.1016/j.bbapap.2009.11.008
pmid: 19922818
|
38 |
WT van der Graaf, JY Blay, SP Chawla, DW Kim, B Bui-Nguyen, PG Casali, P Schöffski, M Aglietta, AP Staddon, Y Beppu, A Le Cesne, H Gelderblom, IR Judson, N Araki, M Ouali, S Marreaud, R Hodge, MR Dewji, C Coens, GD Demetri, CD Fletcher, AP Dei Tos, P Hohenberger; EORTC Soft Tissue and Bone Sarcoma Group; PALETTE Study Group. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2012; 379(9829): 1879–1886
https://doi.org/10.1016/S0140-6736(12)60651-5
pmid: 22595799
|
39 |
J Martin-Liberal, C Benson, H McCarty, K Thway, C Messiou, I Judson. Pazopanib is an active treatment in desmoid tumour/aggressive fibromatosis. Clin Sarcoma Res 2013; 3(1): 13
https://doi.org/10.1186/2045-3329-3-13
pmid: 24279994
|
40 |
MM Gounder, RA Lefkowitz, ML Keohan, DR D’Adamo, M Hameed, CR Antonescu, S Singer, K Stout, L Ahn, RG Maki. Activity of sorafenib against desmoid tumor/deep fibromatosis. Clin Cancer Res 2011; 17(12): 4082–4090
https://doi.org/10.1158/1078-0432.CCR-10-3322
pmid: 21447727
|
41 |
GT Wong, D Manfra, FM Poulet, Q Zhang, H Josien, T Bara, L Engstrom, M Pinzon-Ortiz, JS Fine, HJ Lee, L Zhang, GA Higgins, EM Parker. Chronic treatment with the γ-secretase inhibitor LY-411,575 inhibits β-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J Biol Chem 2004; 279(13): 12876–12882
https://doi.org/10.1074/jbc.M311652200
pmid: 14709552
|
42 |
SJ Pollack, H Lewis. Secretase inhibitors for Alzheimer’s disease: challenges of a promiscuous protease. Curr Opin Investig Drugs 2005; 6(1): 35–47
pmid: 15675602
|
43 |
DB Henley, KL Sundell, G Sethuraman, SA Dowsett, PC May. Safety profile of semagacestat, a γ-secretase inhibitor: IDENTITY trial findings. Curr Med Res Opin 2014; 30(10): 2021–2032
https://doi.org/10.1185/03007995.2014.939167
pmid: 24983746
|
44 |
LW Ellisen, J Bird, DC West, AL Soreng, TC Reynolds, SD Smith, J Sklar. TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell 1991; 66(4): 649–661
https://doi.org/10.1016/0092-8674(91)90111-B
pmid: 1831692
|
45 |
AP Weng, AA Ferrando, W Lee, JP Morris 4th, LB Silverman, C Sanchez-Irizarry, SC Blacklow, AT Look, JC Aster. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 2004; 306(5694): 269–271
https://doi.org/10.1126/science.1102160
pmid: 15472075
|
46 |
P Zagouras, S Stifani, CM Blaumueller, ML Carcangiu, S Artavanis-Tsakonas. Alterations in Notch signaling in neoplastic lesions of the human cervix. Proc Natl Acad Sci USA 1995; 92(14): 6414–6418
https://doi.org/10.1073/pnas.92.14.6414
pmid: 7604005
|
47 |
Y Miyamoto, A Maitra, B Ghosh, U Zechner, P Argani, CA Iacobuzio-Donahue, V Sriuranpong, T Iso, IM Meszoely, MS Wolfe, RH Hruban, DW Ball, RM Schmid, SD Leach. Notch mediates TGF α-induced changes in epithelial differentiation during pancreatic tumorigenesis. Cancer Cell 2003; 3(6): 565–576
https://doi.org/10.1016/S1535-6108(03)00140-5
pmid: 12842085
|
48 |
V Rodilla, A Villanueva, A Obrador-Hevia, A Robert-Moreno, V Fernández-Majada, A Grilli, N López-Bigas, N Bellora, MM Albà, F Torres, M Duñach, X Sanjuan, S Gonzalez, T Gridley, G Capella, A Bigas, L Espinosa. Jagged1 is the pathological link between Wnt and Notch pathways in colorectal cancer. Proc Natl Acad Sci USA 2009; 106(15): 6315–6320
https://doi.org/10.1073/pnas.0813221106
pmid: 19325125
|
49 |
HA Kim, BK Koo, JH Cho, YY Kim, J Seong, HJ Chang, YM Oh, DE Stange, JG Park, D Hwang, YY Kong. Notch1 counteracts WNT/b-catenin signaling through chromatin modification in colorectal cancer. J Clin Invest 2012; 122(9): 3248–3259
https://doi.org/10.1172/JCI61216
pmid: 22863622
|
50 |
R Kopan, MX Ilagan. The canonical Notch signaling pathway: unfolding the activation mechanism. Cell 2009; 137(2): 216–233
https://doi.org/10.1016/j.cell.2009.03.045
pmid: 19379690
|
51 |
J Yao, C Qian, T Shu, X Zhang, Z Zhao, Y Liang. Combination treatment of PD98059 and DAPT in gastric cancer through induction of apoptosis and downregulation of WNT/b-catenin. Cancer Biol Ther 2013; 14(9): 833–839
https://doi.org/10.4161/cbt.25332
pmid: 23792588
|
52 |
JJ Arcaroli, KS Quackenbush, A Purkey, RW Powell, TM Pitts, S Bagby, AC Tan, B Cross, K McPhillips, EK Song, WM Tai, RA Winn, K Bikkavilli, M Vanscoyk, SG Eckhardt, WA Messersmith. Tumours with elevated levels of the Notch and Wnt pathways exhibit efficacy to PF-03084014, a g-secretase inhibitor, in a preclinical colorectal explant model. Br J Cancer 2013; 109(3): 667–675
https://doi.org/10.1038/bjc.2013.361
pmid: 23868008
|
53 |
WA Messersmith, GI Shapiro, JM Cleary, A Jimeno, A Dasari, B Huang, MN Shaik, R Cesari, X Zheng, JM Reynolds, PA English, KR McLachlan, KA Kern, PM LoRusso. A Phase I, dose-finding study in patients with advanced solid malignancies of the oral g-secretase inhibitor PF-03084014. Clin Cancer Res 2015; 21(1): 60–67
https://doi.org/10.1158/1078-0432.CCR-14-0607
pmid: 25231399
|
54 |
S Roussin, C Mazouni, F Rimareix, C Honoré, P Terrier, O Mir, J Dômont, C Le Péchoux, A Le Cesne, S Bonvalot. Toward a new strategy in desmoid of the breast? Eur J Surg Oncol 2015; 41(4): 571–576
https://doi.org/10.1016/j.ejso.2015.01.001
pmid: 25639193
|
55 |
S Okuno. The enigma of desmoid tumors. Curr Treat Options Oncol 2006; 7(6): 438–443
https://doi.org/10.1007/s11864-006-0019-4
pmid: 17032556
|
56 |
D Lev, D Kotilingam, C Wei, MT Ballo, GK Zagars, PW Pisters, AA Lazar, SR Patel, RS Benjamin, RE Pollock. Optimizing treatment of desmoid tumors. J Clin Oncol 2007; 25(13): 1785–1791
https://doi.org/10.1200/JCO.2006.10.5015
pmid: 17470870
|
57 |
MA Rodriguez-Bigas, MC Mahoney, CP Karakousis, NJ Petrelli. Desmoid tumors in patients with familial adenomatous polyposis. Cancer 1994; 74(4): 1270–1274
https://doi.org/10.1002/1097-0142(19940815)74:4<1270::AID-CNCR2820740415>3.0.CO;2-7
pmid: 7519966
|
58 |
MT Ballo, GK Zagars, A Pollack, PW Pisters, RA Pollack. Desmoid tumor: prognostic factors and outcome after surgery, radiation therapy, or combined surgery and radiation therapy. J Clin Oncol 1999; 17(1): 158–167
https://doi.org/10.1200/JCO.1999.17.1.158
pmid: 10458229
|
59 |
A Gronchi, PG Casali, L Mariani, S Lo Vullo, M Colecchia, L Lozza, R Bertulli, M Fiore, P Olmi, M Santinami, J Rosai. Quality of surgery and outcome in extra-abdominal aggressive fibromatosis: a series of patients surgically treated at a single institution. J Clin Oncol 2003; 21(7): 1390–1397
https://doi.org/10.1200/JCO.2003.05.150
pmid: 12663732
|
60 |
JG Johnson, E Gilbert, B Zimmermann, AL Watne. Gardner’s syndrome, colon cancer, and sarcoma. J Surg Oncol 1972; 4(4): 354–362
https://doi.org/10.1002/jso.2930040406
pmid: 5083569
|
61 |
SA Leibel, WM Wara, DR Hill, EG Bovill Jr, AA de Lorimier, JH Beckstead, TL Phillips. Desmoid tumors: local control and patterns of relapse following radiation therapy. Int J Radiat Oncol Biol Phys 1983; 9(8): 1167–1171
https://doi.org/10.1016/0360-3016(83)90175-X
pmid: 6409853
|
62 |
G Pignatti, G Barbanti-Bròdano, D Ferrari, F Gherlinzoni, F Bertoni, P Bacchini, E Barbieri, A Giunti, M Campanacci. Extraabdominal desmoid tumor. A study of 83 cases. Clin Orthop Relat Res 2000; (375): 207–213
https://doi.org/10.1097/00003086-200006000-00025
pmid: 10853171
|
63 |
MC Posner, MH Shiu, JL Newsome, SI Hajdu, JJ Gaynor, MF Brennan. The desmoid tumor. Not a benign disease. Arch Surg 1989; 124(2): 191–196
https://doi.org/10.1001/archsurg.1989.01410020061010
pmid: 2916941
|
64 |
JJ Reitamo. The desmoid tumor. IV. Choice of treatment, results, and complications. Arch Surg 1983; 118(11): 1318–1322
https://doi.org/10.1001/archsurg.1983.01390110066014
pmid: 6639341
|
65 |
A Sørensen, J Keller, OS Nielsen, OM Jensen. Treatment of aggressive fibromatosis: a retrospective study of 72 patients followed for 1−27 years. Acta Orthop Scand 2002; 73(2): 213–219
https://doi.org/10.1080/000164702753671830
pmid: 12079022
|
66 |
AM Crago, B Denton, S Salas, A Dufresne, JJ Mezhir, M Hameed, M Gonen, S Singer, MF Brennan. A prognostic nomogram for prediction of recurrence in desmoid fibromatosis. Ann Surg 2013; 258(2): 347–353
https://doi.org/10.1097/SLA.0b013e31828c8a30
pmid: 23532110
|
67 |
M Fiore, C Colombo, S Radaelli, D Callegaro, E Palassini, M Barisella, C Morosi, GG Baldi, S Stacchiotti, PG Casali, A Gronchi. Hormonal manipulation with toremifene in sporadic desmoid-type fibromatosis. Eur J Cancer 2015; 51(18): 2800–2807
https://doi.org/10.1016/j.ejca.2015.08.026
pmid: 26602014
|
68 |
DR Quast, R Schneider, E Burdzik, S Hoppe, G Möslein. Long-term outcome of sporadic and FAP-associated desmoid tumors treated with high-dose selective estrogen receptor modulators and sulindac: a single-center long-term observational study in 134 patients. Fam Cancer 2016; 15(1): 31–40
https://doi.org/10.1007/s10689-015-9830-z
pmid: 26275868
|
69 |
T Desurmont, JH Lefèvre, C Shields, C Colas, E Tiret, Y Parc. Desmoid tumour in familial adenomatous polyposis patients: responses to treatments. Fam Cancer 2015; 14(1): 31–39
https://doi.org/10.1007/s10689-014-9760-1
pmid: 25315103
|
70 |
A Hansmann, C Adolph, T Vogel, A Unger, G Moeslein. High-dose tamoxifen and sulindac as first-line treatment for desmoid tumors. Cancer 2004; 100(3): 612–620
https://doi.org/10.1002/cncr.11937
pmid: 14745880
|
71 |
JH Howard, RE Pollock. Intra-abdominal and abdominal wall desmoid fibromatosis. Oncol Ther 2016; 4(1): 57–72
https://doi.org/10.1007/s40487-016-0017-z
pmid: 28261640
|
72 |
B Fisher, JP Costantino, DL Wickerham, CK Redmond, M Kavanah, WM Cronin, V Vogel, A Robidoux, N Dimitrov, J Atkins, M Daly, S Wieand, E Tan-Chiu, L Ford, N Wolmark. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998; 90(18): 1371–1388
https://doi.org/10.1093/jnci/90.18.1371
pmid: 9747868
|
73 |
VP de Camargo, ML Keohan, DR D’Adamo, CR Antonescu, MF Brennan, S Singer, LS Ahn, RG Maki. Clinical outcomes of systemic therapy for patients with deep fibromatosis (desmoid tumor). Cancer 2010; 116(9): 2258–2265
https://doi.org/10.1002/cncr.25089
pmid: 20187095
|
74 |
M Gega, H Yanagi, R Yoshikawa, M Noda, H Ikeuchi, K Tsukamoto, T Oshima, Y Fujiwara, N Gondo, K Tamura, J Utsunomiya, T Hashimoto-Tamaoki, T Yamamura. Successful chemotherapeutic modality of doxorubicin plus dacarbazine for the treatment of desmoid tumors in association with familial adenomatous polyposis. J Clin Oncol 2006; 24(1): 102–105
https://doi.org/10.1200/JCO.2005.02.1923
pmid: 16382119
|
75 |
A Constantinidou, RL Jones, M Scurr, O Al-Muderis, I Judson. Pegylated liposomal doxorubicin, an effective, well-tolerated treatment for refractory aggressive fibromatosis. Eur J Cancer 2009; 45(17): 2930–2934
https://doi.org/10.1016/j.ejca.2009.08.016
pmid: 19767198
|
76 |
D Garbay, A Le Cesne, N Penel, C Chevreau, P Marec-Berard, JY Blay, M Debled, N Isambert, A Thyss, E Bompas, O Collard, S Salas, JM Coindre, B Bui, A Italiano. Chemotherapy in patients with desmoid tumors: a study from the French Sarcoma Group (FSG). Ann Oncol 2012; 23(1): 182–186
https://doi.org/10.1093/annonc/mdr051
pmid: 21444357
|
77 |
AJ Weiss, S Horowitz, RD Lackman. Therapy of desmoid tumors and fibromatosis using vinorelbine. Am J Clin Oncol 1999; 22(2): 193–195
https://doi.org/10.1097/00000421-199904000-00020
pmid: 10199460
|
78 |
A Azzarelli, A Gronchi, R Bertulli, JD Tesoro, D Baratti, E Pennacchioli, P Dileo, A Rasponi, A Ferrari, S Pilotti, PG Casali. Low-dose chemotherapy with methotrexate and vinblastine for patients with advanced aggressive fibromatosis. Cancer 2001; 92(5): 1259–1264
https://doi.org/10.1002/1097-0142(20010901)92:5<1259::AID-CNCR1446>3.0.CO;2-Y
pmid: 11571741
|
79 |
MM Bertagnolli, JA Morgan, CD Fletcher, CP Raut, P Dileo, RR Gill, GD Demetri, S George. Multimodality treatment of mesenteric desmoid tumours. Eur J Cancer 2008; 44(16): 2404–2410
https://doi.org/10.1016/j.ejca.2008.06.038
pmid: 18706807
|
80 |
K Tanaka, R Yoshikawa, H Yanagi, M Gega, Y Fujiwara, T Hashimoto-Tamaoki, S Hirota, T Tsujimura, N Tomita. Regression of sporadic intra-abdominal desmoid tumour following administration of non-steroidal anti-inflammatory drug. World J Surg Oncol 2008; 6(1): 17
https://doi.org/10.1186/1477-7819-6-17
pmid: 18257933
|
81 |
D Bocale, MT Rotelli, A Cavallini, DF Altomare. Anti-oestrogen therapy in the treatment of desmoid tumours: a systematic review. Colorectal Dis 2011; 13(12): e388–e395
https://doi.org/10.1111/j.1463-1318.2011.02758.x
pmid: 21831172
|
82 |
S Li, Z Fan, Z Fang, J Liu, C Bai, R Xue, L Zhang, T Gao. Efficacy of vinorelbine combined with low-dose methotrexate for treatment of inoperable desmoid tumor and prognostic factor analysis. Chin J Cancer Res 2017; 29(5): 455–462
https://doi.org/10.21147/j.issn.1000-9604.2017.05.10
pmid: 29142465
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|